• +1-646-491-9876
    • +91-20-67278686

    Search

    Heavy Metal Poisoning - Pipeline Review, H1 2017

    Heavy Metal Poisoning - Pipeline Review, H1 2017

    • Report Code ID: RW0001709420
    • Category Pharmaceuticals
    • No. of Pages 41
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Heavy Metal Poisoning - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Heavy Metal Poisoning - Pipeline Review, H1 2017, provides an overview of the Heavy Metal Poisoning (Toxicology) pipeline landscape.

    Heavy metal poisoning is the accumulation of heavy metals, in toxic amounts, in the soft tissues of the body. Sources of toxicity can include environmental, water supply, industrial and hobbies. Symptoms include headaches, drowsiness, confusion, seizures, nausea, vomiting, abdominal cramps, tinnitus, goiter, anorexia and diarrhea. Treatment includes chelation therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Heavy Metal Poisoning - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Heavy Metal Poisoning (Toxicology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Heavy Metal Poisoning (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Heavy Metal Poisoning and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 4 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

    Heavy Metal Poisoning (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Heavy Metal Poisoning (Toxicology) .
    - The pipeline guide reviews pipeline therapeutics for Heavy Metal Poisoning (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Heavy Metal Poisoning (Toxicology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Heavy Metal Poisoning (Toxicology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Heavy Metal Poisoning (Toxicology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Heavy Metal Poisoning (Toxicology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Heavy Metal Poisoning (Toxicology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Heavy Metal Poisoning - Overview
    Heavy Metal Poisoning - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Heavy Metal Poisoning - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Heavy Metal Poisoning - Companies Involved in Therapeutics Development
    Alnylam Pharmaceuticals Inc
    La Jolla Pharmaceutical Company
    Medesis Pharma SA
    Novartis AG
    PDX Pharmaceuticals LLC
    Heavy Metal Poisoning - Drug Profiles
    ALN-TMP - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    deferasirox - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    deferoxamine mesylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    emeramide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LJPC-401 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NU-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NU-02 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NU-03 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PDX-003 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Heavy Metal Poisoning - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Heavy Metal Poisoning - Dormant Projects
    Heavy Metal Poisoning - Discontinued Products
    Heavy Metal Poisoning - Product Development Milestones
    Featured News & Press Releases
    May 06, 2016: PrJADENU (deferasirox) for the management of chronic iron overload is now available in Canada
    Sep 11, 2015: La Jolla Pharmaceutical Company Receives Positive Opinion from European Orphan Committee for LJPC-401
    Apr 13, 2015: Diplomat to Dispense Novartis Drug, JADENU
    Mar 30, 2015: Novartis announces FDA approval for Jadenu to simplify treatment administration for patients with chronic iron overload
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Heavy Metal Poisoning, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Heavy Metal Poisoning - Pipeline by Alnylam Pharmaceuticals Inc, H1 2017
    Heavy Metal Poisoning - Pipeline by La Jolla Pharmaceutical Company, H1 2017
    Heavy Metal Poisoning - Pipeline by Medesis Pharma SA, H1 2017
    Heavy Metal Poisoning - Pipeline by Novartis AG, H1 2017
    Heavy Metal Poisoning - Pipeline by PDX Pharmaceuticals LLC, H1 2017
    Heavy Metal Poisoning - Dormant Projects, H1 2017
    Heavy Metal Poisoning - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Heavy Metal Poisoning, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Alnylam Pharmaceuticals Inc
    La Jolla Pharmaceutical Company
    Medesis Pharma SA
    Novartis AG
    PDX Pharmaceuticals LLC

    Request for Sample

    Report Url http://www.reportsweb.com//heavy-metal-poisoning-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//heavy-metal-poisoning-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//heavy-metal-poisoning-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments